XmAb27564

BIOLOGICAL2 trials

Sponsors

Xencor, Inc.

Conditions

Atopic DermatitisPsoriasisSafety in Healthy Volunteers

Phase 1

Safety, Tolerability and PK of a Single Subcutaneous Injection of XmAb27564 in Healthy Volunteers

CompletedNCT04857866

Xencor, Inc.Safety in Healthy Volunteers

Start: 2021-04-19End: 2022-11-10Updated: 2023-03-01

Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis

TerminatedNCT06005792

Xencor, Inc.Atopic Dermatitis, Psoriasis

Start: 2022-10-10End: 2024-11-22Updated: 2025-12-02